Cardiff Oncology Inc
NASDAQ:CRDF
Cardiff Oncology Inc
NASDAQ:CRDF
Price:
1.71
USD
-1.16%
Market Closed
Market Cap:
$116.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
US |
|
R
|
Redefine Properties Ltd
JSE:RDF
|
ZA |
Multiples-Based Value
The
Multiples-Based Value for
Cardiff Oncology Inc (CRDF)
under the Base Case is
0.02
USD.
Compared with the current market price of 1.71 USD, the stock appears
Overvalued by 99%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CRDF
Multiples-Based Value
0.02
USD
Overvaluation 99%
Multiples Across Competitors
CRDF Competitors Multiples
Cardiff Oncology Inc Competitors
Cardiff Oncology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
116.8m USD | 196.9 | -2.5 | -1.2 | -1.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 6 | 87.3 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 4.8 | 22.8 | 16.6 | 16.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 5.6 | 19.2 | 12 | 14.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 9 | 27.2 | 20.4 | 21.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.2 | 16.5 | 11.9 | 13.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | 40.3 | 41.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 2.7 | 29.5 | 10.1 | 12.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
